Brepocitinib not checked

Pfizer · PF-06700841

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 2/3 trial completes
Trials
2 active
15 in total · 3 in the EU
Targets
 

What this is

How it works
Blocks JAK enzymes that pass on immune signals, to calm an overactive immune system.-citinib: Janus kinase inhibitors WHO name stem
Tested for
Lichen Planopilaris, Cutaneous Sarcoidosis
Main trialPhase 2/3
“This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with lichen planopilaris”In the company’s words, NCT07532603 on ClinicalTrials.gov
Other names
PF-06700841

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials15

TrialPhaseCompletesWhat it tests
Phase 2/3Recruiting 31 Dec 2028 A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris
Phase 2/3Recruiting 31 Dec 2028 A Study of Brepocitinib in Adults With Cutaneous Sarcoidosis
Phase 3Completed 17 Jul 2025 A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis
Phase 2Completed 6 Apr 2020 A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis
Phase 2Completed 7 May 2020 Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis
Phase 2Completed 5 Feb 2021 A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects
Phase 2Completed 20 Apr 2021 Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis
Phase 2Completed 10 May 2021 Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis
Phase 2Completed 10 Jan 2022 A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa
Phase 2Completed 5 Oct 2023 A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase 2Completed 19 Oct 2023 Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease
Phase 2Completed 30 Jul 2024 A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis
Phase 2Completed 28 Feb 2025 A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant Dermatomyositis
Phase 1Completed 11 Jan 2021 Clinical Study to Evaluate Pharmacokinetics and Safety of PF-06700841 After Single and Multiple Oral Doses as Modified Release Formulations
Phase 1Completed 4 May 2022 Renal Impairment Study of PF-06700841
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Brepocitinib

Following is part of Solo: you see every change to Brepocitinib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in